Marathon Money Exclusive: OS Therapies (NYSE: OSTX) CBO Interview Reveals FDA Meeting In Q2 2025 Milestones, $150M Revenue Boost, and $500M Market Opportunity
In this in-depth conversation, we dive straight into the company’s bold plans for the next 12 to 18 months: Spoiler Alert: Minute 29 is a must-watch. This is where we…







